Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty).
The intervention showed no clear difference in leaving the study early: any reason (medium term) (low certainty).
CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' showed no clear difference in leaving the study early: any reason ‐ medium term compared with ANTIPSYCHOTIC 'B' for (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with typical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).
RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).
It is very uncertain whether levomepromazine changes leaving the study early ‐ medium term ‐ any reason compared with typical antipsychotics (very low certainty).
It is very uncertain whether the intervention changes acceptability of treatment: Leaving the study early (very low certainty).
It is very uncertain whether CHOLINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
It is very uncertain whether DOPAMINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
It is very uncertain whether DOPAMINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with OTHER DRUGS (very low certainty).
It is very uncertain whether NORADRENERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
It is very uncertain whether horticultural therapy plus standard care changes satisfaction with treatment Leaving the study early compared with standard care alone (very low certainty).
The intervention showed no clear difference in leaving the study early ‐ Adverse event: Short‐term; GRADE not reported.
It is very uncertain whether haloperidol discontinuation changes satisfaction with treatment: leaving the study early compared with haloperidol continuation (very low certainty).
It is very uncertain whether aspirin plus antipsychotics changes leaving the study early: short‐term – for any reason compared with placebo plus antipsychotics (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.